Benign versus malignant intraosseous lesions: Discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose

Radiology

Volumn 200, Issue 1, 1996, Pages 243-247

  Dehdashti, Farrokh ^a   Siegel, Barry A ^a   Griffeth, Landis K ^a   Fusselman, Maureen J ^a   Trask, Diana D ^a   McGuire, Andrea H ^a   McGuire, Daniel J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone neoplasms, diagnosis; Bone neoplasms, radionuclide study; Bones, emission CT (ECT); Fluorine; Fractures

Indexed keywords

FLUORODEOXYGLUCOSE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE CANCER; BONE SCINTISCANNING; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; FEMALE; FRACTURE; GLYCOLYSIS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0029938411     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.200.1.8657920     Document Type: Article

References (19)

1. Warbürg O. The metabolism of tumors. New York, NY: Richard R. Smith; 1931: 129-169.
2. Isselbacher KJ. Increased uptake of amino acids and 2-deoxy-D-glucose by virus-transformed cells in culture. Proc Natl Acad Sci 1972; 69:585-589.
3. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29:181-186.
4. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32:1508-1512.
5. Shreve P, Grossman HB, Wahl RL. Initial assessment of FDG/PET detection of skeletal metastatic prostate carcinoma (abstr). J Nucl Med 1993; 34:223P.
6. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179:765-770.
7. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36:1766-1774.
8. 18F]fluoro-2-deoxy-D-glucose. Int J Rad Appl Instrum 1989; 40:741-743.
9. Kubota K, Matsuzawa T, Ito M, et al. Lung tumor imaging by positron emission tomography using C-11 L-methionine. J Nucl Med 1985; 26:37-42.
10. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose [F-18]: nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670-675.
11. Larson SM, Weiden PL, Grunbaum Z, et al. Positron imaging feasibility studies. II. Characteristics of deoxyglucose uptake in rodent and canine neoplasms: concise communication. J Nucl Med 1981; 22:875-879.
12. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of glucose transporter gene. J Biol Chem 1988; 27:13655-13662.
13. Brown RS, Wahl RL. Overexpression of glut-7-glucose transporter in human breast cancer. Cancer 1993; 15:2979-2985.
14. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992; 182:185-194.
15. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972-1980.
16. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35:1647-1649.
17. Meyer M, Gast T, Raja S, Hubner K. Increased F-18 FDG accumulation in an acute fracture. Clin Nucl Med 1994; 19:13-14.
18. Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188:487-490.
19. Jones SC, Alavi A, Christman D, Montanez I, Wolf AP, Reivich M. The radiation dosimetry of 2-[F-18]fluoro-2-deoxy-D-glucose in man. J Nucl Med 1982; 23:613-617.